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Abstract
Background
HIV Elite Controllers may reveal insights into virus persistence given they harbour small res-
ervoir sizes, akin to HIV non-controllers treated early with combination antiretroviral therapy.
Both groups of patients represent the most promising candidates for interventions aimed at
sustained remission or ‘cure’. Analytic treatment interruption (ATI) in the latter group leads
to stochastic rebound of virus, though it is unclear whether loss of elite control is also associ-
ated with similar rebound characteristics.
Methods
We studied three discrete periods of virus rebound during myeloma related immune disrup-
tion over 2.5 years in an elite controller who previously underwent autologous stem cell
transplantation (ASCT) in the absence of any antiretroviral therapy. Single genome
sequencing of the V1-V4 region of env in PBMC and plasma was performed and phyloge-
nies reconstructed. Average pairwise distance (APD) was calculated and non-parametric
methods used to assess compartmentalisation. Coreceptor usage was predicted based on
genotypic algorithms.
Results
122 single genome sequences were obtained (median 26 sequences per rebound). The ini-
tial rebounding plasma env sequences following ASCT represented two distinct lineages,
and clustered with proviral DNA sequences isolated prior to ASCT. One of the lineages was
monophyletic, possibly indicating reactivation from clonally expanded cells. The second
rebound occurred 470 days after spontaneous control of the first rebound and was phyloge-
netically distinct from the first, confirmed by compartmentalisation analysis, with a different
cellular origin rather than ongoing replication. By contrast, third rebound viruses clustered
with second rebound viruses, with evidence for ongoing evolution that was associated with
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lymphopenia and myeloma progression. Following ASCT a shift in tropism from CXCR4-
tropic viruses to a CCR5-tropic population was observed to persist through to the third
rebound.
Conclusions
Our data highlight similarities in the viral reservoir between elite and non-controllers under-
going ATI following allogeneic transplantation. The lack of propagation of CXCR4 using
viruses following transplantation warrants further study.
Introduction
Human immunodeficiency virus (HIV) persistence in long-lived infected immune cells repre-
sents one of the major barriers to HIV eradication. It is widely thought that latently infected
resting memory CD4+ T cells, established early in HIV infection, represent the primary long
lived reservoir and are responsible for the rebounding virus when combined antiretroviral ther-
apy (cART) is interrupted [1–5]. Joos et al. revealed different lineages present during analytic
treatment interruption (ATI) cycles, implying stochastic reactivation of different cellular clones
and therefore release of clonal virus from latently infected cells.
Elite Controllers (EC) account for 0.5–1% of infected HIV-1 individuals, and are able to
control viral replication and maintain immune function for extended periods of time [6–8]. EC
may reveal insights into HIV persistence given they have similar reservoir sizes compared to
individuals on cART [9]. Both groups of patients represent the most promising candidates for
interventions aimed at sustained remission, though there may be qualitative differences in
their reservoirs. Importantly, it is not known whether loss of viral control in EC results in viral
rebound characteristic is similar to that observed in ATI, for example whether rebounds are
stochastic and monophyletic in nature.
We previously reported the viral kinetics and immunological correlates of viral recrudes-
cence in an EC following myeloablation and autologous stem cell transplantation (ASCT) in
the absence of ART [10] and (S1 Fig). Following this initial viral rebound, immune mediated
control was achieved with kinetics similar to that of three drug ART and maintained for more
than a year. The individual subsequently presented with relapsed multiple myeloma and was
found to have loss of HIV-1 control. Here we have analysed in detail the rebounding virus
between the initial ASCT and ensuing periods of relapsed myeloma.
Materials and Methods
Nucleic acid extraction and single genome sequencing
We used single genome sequencing (SGS) of the V1-V4 region of env as described [11, 12].
This method is unbiased by PCR introduced recombination or resampling of sequences [11,
13, 14].
Viral RNA was extracted from plasma using the QIAamp Viral RNA Kit (Qiagen, Hilden,
Germany) and reverse transcribed at 50°C for 60 min followed by 55°C for 60 min using (10
units/ul) SuperScript III (Invitrogen, California, USA) in the supplied 1× RT buffer with
0.5mM dNTPs, 5mM DTT, 2 units/μl RNaseOut (Invitrogen, California, USA) and 0.25μM of
OMF19 [11]. Following reverse transcription the SuperScript III was inactivated at 85°C for 10
min, and the cDNA was treated with 2 units of RNaseH (Invitrogen, California, USA) at 37°C
for 30 min.
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Viral DNA was extracted from peripheral blood mononuclear cells (PBMCs) which were
isolated from 50ml EDTA blood using a standard Ficoll-hypaque separation method utilizing
Lymphoprep (STEMCELL Technologies, Cambridge UK). Total DNA was then extracted from
PBMCs using the Qiagen DNeasy kit (Qiagen, Hilden, Germany).
PCR reactions were carried out using High Fidelity Platinum Taq DNA polymerase (Invi-
trogen, California, USA) and primers Env5out and OMF19 [11], followed by primers Env5in
and Env3in for the nested PCR. The PCR amplifications were carried out in 1× High Fidelity
Platinum PCR buffer, 2mMMgSO4, 0.2mM dNTPs, 0.2μM of each primer and 0.025 units/μl
Platinum Taq. The PCR conditions were as follows: 94°C for 2 minutes, followed by 35 cycles
of 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 4 minutes, finishing with a 10 minute
elongation step at 68°C. All PCR products were run on precast 1% agarose E-gel 96 (Invitrogen,
California, USA) and then the V1-V4 region of the HIV envelope was sequenced using primers
REV16 and FOR14 [12].
Sequence analysis
Chromatograms were manually checked for the presence of mixed bases, any sequences con-
taining mixed bases, indicating the presence of multiple templates, were excluded from further
analysis. All sequences were submitted to Genbank and can be found under accession numbers
KX267967—KX268088. Sequences were assembled using an in-house program and aligned in
MEGA 5.2 (http://www.megasoftware.net) [15]. Neighbour joining (NJ) trees were also made
in MEGA 5.2 and branch support was tested by 1000 bootstraps. Maximum Likelihood trees
were made using the GTRGAMMAmodel in RAxML [16] branch support was inferred by
1000 bootstraps. All trees were rooted on an outgroup, the molecular clone MJ4 [17]; in order
to rule out contamination a separate NJ tree was made that included commonly used plasmids
within our laboratory (data not shown). Trees were annotated and edited using FigTree [18].
Population genetic diversity and divergence were calculated as average pairwise difference
(APD) in MEGA 5.2. The presence of hypermutants was determined using Hypermut software
within the Los Alamos website [19].
We assessed population shifts (geographic subdivision), and migration using the non-
parametric tree based methods; Simmonds Association Index (SAI) [20], Slatkin Maddison
(SM) [21]. In addition we used two nucleotide distance based methods, which do not rely upon
phylogeny, Wrights FSt and Nearest Neighbour (Snn). Distances were estimated using a maxi-
mum likelihood approach under a general time reversible (GTR) nucleotide substitution
model, estimating all parameters independently for each branch. The four tests were performed
within HyPhy [22]. To predict viral tropism we used two genotypic algorithms Geno2pheno
[23] and Phenoseq [24, 25]. Concurrence between both programs was required in order to
assign CXCR4 tropism to a particular env sequence.
Quantification of HIV nucleic acids
HIV-1 RNA and total HIV-1 DNA were quantified as previously described [10, 26].
Ethics statement
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Results
Perturbations in elite control correlate with myeloma relapses
As previously reported [10], the study subject experienced viral recrudescence, peaking at
28,000 c/ml, with spontaneous resolution by day +37 following ASCT (S1 Fig). Fig 1 illustrates
HIV viral load (c/ml), CD4+ and CD8+ counts (cells/ul), as well as paraprotein levels (g/L)
during the period of days +354 to +966 post ASCT. On day +503 routine tests revealed a HIV-
1 plasma viral load of 4400 c/ml, HIV-1 total DNA of 100 c/1e6 PBMCs, a CD4+ count of
730mm3 (25%) and CD8+ cell count of 1170mm3 (40%) whilst paraprotein was noted to have
increased to 52g/L. At this point a diagnosis of biochemical relapse of multiple myeloma was
made. The viral load steadily increased and at day +521 peaked at 12,000 c/ml in plasma, with
a doubling time of 10.5 days (in contrast to 0.5 days for the first rebound). The individual was
given two cycles of bortezomib (2.75mg), dexamethasone (20mg) and cyclophosphamide
(500mg), followed by four cycles of bi-weekly bortezomib (2.75mg) (Fig 1A). The paraprotein
levels did not improve in the short term and HIV-1 viral load declined over the following
weeks reaching<50 c/ml by day +601 (Fig 1B and 1C). The decay rate was much slower than
that observed following the initial rebound associated with ASCT. Further treatment for mye-
loma with lenalidomide was commenced and later substituted for thalidomide (100mg) on day
+635 due to an adverse drug reaction. Over the following months the viral load followed a fluc-
tuating course, mirroring paraprotein levels (Fig 1B). Despite paraprotein levels reaching 13g/L
and HIV viral load declining to 69 c/ml on day +832, paraprotein levels and HIV viral load
went on to steadily increase. During this disease course the individual was offered and refused
cART. Unfortunately the individual succumbed to multiple myeloma on day +1004.
Single genome amplification reveals stochastic HIV-1 rebound from
limited sources
We obtained a total of 122 single genome env sequences, with a median of 26 sequences per rebound
(range 10–62, Fig 2). Average pairwise distance (APD) did not increase between first and second
rebound time points relative to pre-ASCT (Fig 2). Phylogenetic analysis, depicted in Fig 3 and S2
Fig, of env sequences isolated prior to ASCT (open orange diamonds) indicated that rebounding
plasma env sequences (blue diamonds) represented three distinct clusters and this compartmentali-
zation of rebound was confirmed by four non-parametric analyses, shown in Table 1. One of these
plasma RNA derived clusters consisted of a large monophyletic population, possibly, consistent with
viral rebound from a single latently infected cellular clone (Fig 3, blue diamonds upper part of tree).
These data demonstrate virus and cellular persistence despite treatment with melphalan and ASCT.
In order to determine if the rebounding viruses isolated during relapse of multiple myeloma
(second and third rebounds, pink and green shaded area Fig 1A) had diverged from those iso-
lated during the initial rebound, we next analysed env sequences from five time points, the first
being prior to the second peak viraemia on day +515 and the last at day +958 (Fig 3).
Env sequences obtained from plasma RNA during the second rebound (day +515, Fig 3,
depicted by pink symbols) form two separate clusters from the majority of env sequences
obtained from plasma RNA during the first rebound (day +6). The phylogenetic tree indicated
divergence between the viral populations sequenced from the first and second rebounds, possi-
bly indicating plasma viruses originating from separate cellular populations (Fig 3 and S2 Fig).
This change in the viral population was confirmed by compartmentalisation analysis (Table 1).
The majority of RNA sequences obtained from the second rebound were found together as a
monophyletic rake of eight identical sequences, accounting for 47% of the second rebound env
sequences sampled. Possibly suggesting that these RNA sequences had the same cellular origin.
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The genetic distance, measured as APD, increased from 0.7% to 1.5% (Fig 2) during the
third rebound period, indicating more widespread replication from multiple sources. This was
co-incident with myeloma progression, possibly indicating further immune compromise and
loss of viral control.
Corresponding with the marked increase in APD during the third rebound, proviral env
sequences obtained from PBMC during the same period (Fig 3 –open green diamonds) intermin-
gled with RNA sequences obtained from plasma during the second rebound, supporting viral repli-
cation at this later time point, rather than activation of latently infected cells during this period.
Importantly, there were two clusters of identical sequences from the second and third
rebounds, consistent with persistence of cellular clones during chemotherapy. As predicted,
compartmentalisation analysis of sequences obtained during the second and third rebound
(Table 1) did not demonstrate evidence of population shift or migration during this time.
Shift in coreceptor usage from CXCR4 to CCR5 following myeloablation
88.9% of proviral sequences, obtained an average of 36 days (range 27–44 days), prior to the
ASCT demonstrated genotypic tropism for the co-receptor CXCR4 (Figs 3 and 4). By contrast,
Fig 1. HIV viral rebound following relapsedmyeloma (A) Diagram representing prescribed drugs known to have immunological
effects extended horizontally to represent time and correspond with days post ASCT as represented in graphs (B) and (C). Additionally
the time of myeloma relapse and the second (magenta) and third (green) rebound periods are highlighted. (B). Graphical
representation of longitudinal HIV plasma RNA viral load and CD4+ T-cells counts. Magenta and green shaded boxes indicate the
second and third rebound time points and correspond to (A). (C). (A) scatter plot of longitudinal CD8+ T cell count and paraprotein
levels over days post ASCT, the shaded boxes correspond to (A).
doi:10.1371/journal.pone.0158854.g001
Fig 2. Diversity measured as average pairwise distance at longitudinal time points. APDmeasured pre-
ASCT and during subsequent viral rebounds. Numbers in parentheses indicate the number of single
genomes acquired at each time point. Significance was determined by two-tailed.
doi:10.1371/journal.pone.0158854.g002
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during the initial rebound following ASCT only 5.7% of the RNA virus found in plasma dem-
onstrated genotypic tropism for CXCR4 (Fig 3 and Fig 4), suggesting that CCR5-using virus
preferentially reactivated and replicated or that cells harbouring CCR5 virus preferentially sur-
vived the transplantation process. Sequences obtained from the second rebound were 100%
CCR5 tropic and the third rebound was also dominated by CCR5 using viruses (95.2% CCR5),
even in the context of a depressed CD4 count (180 cells/uL).
Discussion
We observed stochastic reactivation of virus replication in an individual with natural control of
HIV-1 during immune disruption occurring over a period of 2.5 years. Compartmentalised,
monophyletic HIV-1 RNA envs from the first and second rebounds suggest similarities in the
viral reservoir between EC and non-controllers undergoing treatment interruption following
allogeneic transplantation, as reported by Henrich and colleagues [27]. In the aforementioned
study, the authors deduced that only one, or a small number of cells/latent proviruses, contrib-
uted to viral rebound after ATI.
Viral diversity in our individual was low and remained stable until the third rebound of
plasma virus, when diversity increased from 0.7% to 1.5%. This may reflect a global loss of con-
trol that was likely multi-factorial. During the third rebound the individual was treated with
thalidomide for relapse of multiple myeloma and his CD4+ T cell count was at its lowest
(around 200 cells /ul). Additionally, and importantly, during the third rebound the viral load
did not become fully suppressed, the lowest viral load being 69 c/ml (Fig 1). Therefore, the
third rebound likely represents the result of ongoing viral replication rather than activation of
latently infected cells. This is supported by the phylogeny in which we observe third rebound
viruses to be well mingled between other rebound time points, and further supported by geo-
graphic subdivision analysis which did not identify the third rebound as emerging from an
individual compartment. Immunomodulatory agents (IMiDs) have been reported to activate T
cells [28–30], this individual received lenalidomide and thalidomide prior and during the third
rebound which may partly explain our observation of increasing viral diversity.
Fig 3. Inferred neighbour-joining phylogenetic tree of single genome derived HIV-1 env sequences. Two APOBEC
hypermutated sequences found in the third rebound have been removed. Pre melphalan HIV DNA (-27 to -38, orange open
diamonds), first rebound HIV RNA (+6, blue closed diamonds), first rebound HIV DNA (+6, blue open diamonds), second rebound
HIV RNA (+515, magenta closed diamonds), third rebound HIV DNA (+643 to +958, green open diamonds). Rooted on MJ4
(black square), branches with bootstrap support > 75% are indicated by black asterisk. Overall population APD is 1.5%. The scale
represents 0.005 nucleotide substitutions per site, equivalent to 4.5nt. The tips in the boxed grey area representative sequences
predicted to confer CXCR4 tropism by both Geno2Pheno and Phenoseq genotypic algorithms.
doi:10.1371/journal.pone.0158854.g003
Table 1. Non-parametric geographic subdivision tests comparing pre- ASCT viruses with those at each rebound.
SM SAI Wrights FSt Nearest Neighbour (Snn)
Time Point ME (<11) p (<0.05) AI (<0.6) BS (>95) p (<0.05) p (<0.05)
Pre–ASCT vs First Rebound 3 0.000 0.131 100 0.000 0.001
Pre–ASCT vs Second Rebound 2 0.000 0.124 100 0.000 0.001
Pre–ASCT vs Third Rebound 6 0.000 0.176 100 0.134 0.000
First Rebound vs Second Rebound 4 0.007 0.554 97 0.142 0.001
First Rebound vs Third Rebound 6 0.000 0.231 100 0.257 0.000
Second Rebound vs Third Rebound 8 0.403 0.68 89 0.689 0.084
SM- Slatkin Maddison, SAI–Simmonds Association Index, ME: Migration Events, AI: Association Index, BS: Bootstrap Significance (1000). Wrights FSt. p:
Probability based on 10,000 permutations was computed, with the permutation test randomly allocating sequences into each group compared.
Hypermutants removed and identical sequences collapsed.
doi:10.1371/journal.pone.0158854.t001
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Finally, we observed an unexpected parallel between our case and the ‘Berlin patient’, the
only individual thought to have achieved HIV ‘cure’. Tropism testing of the viral population
within the Berlin patient [31] prior to transplant with a homologous CCR5 delta32 donor
revealed a minority (2.9%) of X4 tropic species within plasma RNA, but not in proviral DNA.
This individual has not experienced virus rebound despite the presence of X4 virus in plasma.
In our individual, genotypic tropism testing of proviral sequences obtained pre-transplant
revealed a majority X4 population. Following ASCT a shift in tropism from CXCR4 using pro-
viruses to a population mostly using CCR5 occurred, despite a minority X4 species remaining
in RNA as well as DNA, indicating that these viruses were replication competent. It could be
that the X4 viruses were not as fit as the R5 viruses that rebounded in our individual, or that
there was a larger reservoir of R5 pre-transplant proviruses in an unsampled compartment
such as lymph node. Another possibility is that cells harboring X4 viruses are less likely to sur-
vive the effects of chemotherapy. Finally one should consider the possibility that the rebound
originated in myeloid cells infected with R5 tropic virus.
Conclusion
Although the data are derived from a single case, they highlight similarities in the viral reservoir
between elite and non-controllers undergoing ATI following stem cell transplantation. Insights
from rare individuals such as EC will continue to be very informative in elucidating the nature of
HIV-1 reservoirs as we search for a curative HIV intervention. Given the preferential reactivation
of CCR5 tropic viruses in both our case and previous ATI studies, CCR5 antagonists may be use-
ful in curative interventions even where CXCR4 and CCR5 variants coexist.
Supporting Information
S1 Fig. Dynamic changes in HIV nucleic acids and total lymphocytes following ASCT.
Administration of melphalan at day 0. (A) Longitudinal PCR quantification of HIV RNA and
Fig 4. Genotypically defined co-receptor usage following HIV rebounds. Tropism testing of the HIV V3
loop was performed in both Geno2Pheno and Phenoseq online genotypic algorithms. Percentage of CXCR4
sequences is plotted on the Y-axis. Only sequences found to be X4 in both programs were designated as X4.
Significance was determined using a two-tailed Fishers Exact test.
doi:10.1371/journal.pone.0158854.g004
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DNA, and total lymphocyte numbers following the first 50 days post ASCT. (B) Plasma HIV-1
RNA over time ASCT. First and second phase decay is displayed by dotted lines.
(TIF)
S2 Fig. Inferred maximum likelihood phylogenetic tree of single genome derived HIV-1
env sequences. Identical sequences have been collapsed and a single representative sequence
left in the alignment to build the tree. Identical sequences have then been extended horizontally
across the tree at the tip at which they appeared. Pre melphalan HIV DNA (-27 to -38, orange
open diamonds), first rebound HIV RNA (+6, blue closed diamonds), first rebound HIV DNA
(+6, blue open diamonds), second rebound HIV RNA (+515, magenta closed diamonds) and
third rebound HIV DNA (+643 to +958, green open diamonds). Rooted on MJ4, indicated by a
black square. Branches with bootstrap support> 75% are represented by black asterisk. Open
squares represent APOBEC hypermutated sequence. The overall population has a APD of
1.5% (with the hypermutants removed). The scale represents 0.005 nucleotide substitutions per
site, equivalent to 4.5nt.
(TIF)
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